AlphaQuest LLC Raises Stock Position in IQVIA Holdings Inc. $IQV

Key Points

• AlphaQuest LLC increased its ownership in IQVIA Holdings Inc. by 101.8%, acquiring a total of 13,349 shares worth approximately $2.35 million, according to a recent SEC filing.
• In the latest quarterly earnings report, IQVIA reported an earnings per share (EPS) of $2.81, exceeding analyst expectations, with revenues of $4.02 billion, up 5.3% year-over-year.
• Price targets for IQVIA have been raised by multiple analysts, with an average target now at $228.62, reflecting a consensus rating of "Moderate Buy" among 17 analysts.

AlphaQuest LLC increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 101.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,349 shares of the medical research company's stock after acquiring an additional 6,735 shares during the quarter. AlphaQuest LLC's holdings in IQVIA were worth $2,353,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Sowell Financial Services LLC purchased a new stake in IQVIA during the 1st quarter worth approximately $305,000. Mather Group LLC. boosted its holdings in shares of IQVIA by 83.5% in the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after acquiring an additional 350 shares during the last quarter. Private Advisor Group LLC boosted its holdings in shares of IQVIA by 11.6% in the 1st quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company's stock valued at $958,000 after acquiring an additional 566 shares during the last quarter. Park Avenue Securities LLC boosted its holdings in shares of IQVIA by 40.4% in the 1st quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock valued at $956,000 after acquiring an additional 1,562 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of IQVIA by 34.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock valued at $2,338,000 after acquiring an additional 3,398 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Stock Up 0.2%

NYSE IQV traded up $0.35 during trading hours on Wednesday, hitting $188.11. 545,656 shares of the company were exchanged, compared to its average volume of 1,947,844. The company has a 50 day moving average of $174.96 and a two-hundred day moving average of $167.97. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88. The firm has a market cap of $31.98 billion, a price-to-earnings ratio of 27.22, a PEG ratio of 2.06 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter in the previous year, the firm earned $2.64 EPS. The company's revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently commented on IQV. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Redburn Partners set a $188.00 target price on shares of IQVIA in a report on Friday, May 23rd. Mizuho lifted their target price on shares of IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a report on Friday, July 25th. UBS Group lifted their target price on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Finally, Truist Financial lifted their target price on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $228.62.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.